Sanofi (NASDAQ:SNY) Rating Increased to Strong-Buy at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Sanofi (NASDAQ:SNY) to a strong-buy rating in a research note published on Thursday morning,Zacks.com reports.

A number of other brokerages also recently weighed in on SNY. Citigroup began coverage on shares of Sanofi in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. TD Cowen reissued a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $61.50.

Sanofi Stock Performance

SNY opened at $44.60 on Thursday. The firm has a fifty day moving average price of $46.46 and a 200 day moving average price of $48.05. Sanofi has a 1 year low of $43.32 and a 1 year high of $57.60. The stock has a market cap of $108.78 billion, a P/E ratio of 12.39, a P/E/G ratio of 1.17 and a beta of 0.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73.

Institutional Investors Weigh In On Sanofi

Several large investors have recently bought and sold shares of the company. CSM Advisors LLC purchased a new stake in shares of Sanofi in the third quarter valued at about $18,244,000. Caprock Group LLC purchased a new position in Sanofi during the third quarter worth about $1,347,000. Natixis Advisors LLC boosted its holdings in Sanofi by 11.8% in the 3rd quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock valued at $146,952,000 after purchasing an additional 327,569 shares during the last quarter. Assetmark Inc. boosted its holdings in Sanofi by 25.0% in the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock valued at $16,859,000 after purchasing an additional 71,356 shares during the last quarter. Finally, Regal Partners Ltd grew its stake in shares of Sanofi by 7.1% in the 3rd quarter. Regal Partners Ltd now owns 1,657,539 shares of the company’s stock valued at $78,236,000 after buying an additional 109,335 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.